Fluoropharm will participate in the 24th CPHI China 2026, which will be held in Shanghai, China from

Ovarian cancer is known as the 'silent killer' due to the hidden nature of its early symptom

Recently, the FDA released a draft guidance titled 'Development of Non-Opioid Analgesics for the

Ifinatamab deruxtecan is a potentially first-in-class antibody-drug conjugate (ADC) targeting B7-H3,

Sodium fluorine [18F] injection is a positron emission tomography (PET) radioimaging agent used in b

On June 27, 2025, China's National Medical Products Administration (NMPA) announced the approval

Recently, researchers found that after 18 months of treatment with evolocumab, patients with coronar

Our company will participate in CPHI China 2025 in Shanghai New International Expo Center from June

Preclinical studies have shown that the anti-tumor activity of CS2009 is superior to that of potenti

Semaglutide is a hypoglycemic drug developed by Novo Nordisk. The drug is a glucagon-like peptide-1